Yunzhao Luo, Jing Wei, Yang Gu, Chuang Zhu, Feng Xu
{"title":"Predicting molecular subtype in breast cancer using deep learning on mammography images.","authors":"Yunzhao Luo, Jing Wei, Yang Gu, Chuang Zhu, Feng Xu","doi":"10.3389/fonc.2025.1638212","DOIUrl":null,"url":null,"abstract":"<p><strong>Objectives: </strong>This study aimed to develop and evaluate a deep learning model for predicting molecular subtypes of breast cancer using conventional mammography images, offering a potential alternative to invasive diagnostic techniques.</p><p><strong>Methods: </strong>A retrospective analysis was conducted on 390 patients with pathologically confirmed invasive breast cancer who underwent preoperative mammography. The proposed DenseNet121-CBAM model, integrating Convolutional Block Attention Modules (CBAM) with DenseNet121, was trained and validated for binary (Luminal vs. non-Luminal, HER2-positive vs. HER2-negative, triple-negative vs. non-TN) and multiclass (Luminal A, Luminal B, HER2+/HR+, HER2+/HR-, TN) classification tasks. Performance metrics included AUC, accuracy, sensitivity, specificity, and interpretability via Grad-CAM heatmaps.</p><p><strong>Results: </strong>The model achieved AUCs of 0.759 (Luminal vs. non-Luminal), 0.658 (HER2 status), and 0.668 (TN vs. non-TN) in the independent test set. For multiclass classification, the AUC was 0.649, with superior performance in distinguishing HER2+/HR- (AUC = 0.78) and triple-negative (AUC = 0.72) subtypes. Attention heatmaps highlighted peritumoral regions as critical discriminative features.</p><p><strong>Conclusion: </strong>The DenseNet121-CBAM model demonstrates promising capability in predicting breast cancer molecular subtypes from mammography, offering a non-invasive alternative to biopsy.</p>","PeriodicalId":12482,"journal":{"name":"Frontiers in Oncology","volume":"15 ","pages":"1638212"},"PeriodicalIF":3.5000,"publicationDate":"2025-09-16","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12479247/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Frontiers in Oncology","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.3389/fonc.2025.1638212","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2025/1/1 0:00:00","PubModel":"eCollection","JCR":"Q2","JCRName":"ONCOLOGY","Score":null,"Total":0}
引用次数: 0
Abstract
Objectives: This study aimed to develop and evaluate a deep learning model for predicting molecular subtypes of breast cancer using conventional mammography images, offering a potential alternative to invasive diagnostic techniques.
Methods: A retrospective analysis was conducted on 390 patients with pathologically confirmed invasive breast cancer who underwent preoperative mammography. The proposed DenseNet121-CBAM model, integrating Convolutional Block Attention Modules (CBAM) with DenseNet121, was trained and validated for binary (Luminal vs. non-Luminal, HER2-positive vs. HER2-negative, triple-negative vs. non-TN) and multiclass (Luminal A, Luminal B, HER2+/HR+, HER2+/HR-, TN) classification tasks. Performance metrics included AUC, accuracy, sensitivity, specificity, and interpretability via Grad-CAM heatmaps.
Results: The model achieved AUCs of 0.759 (Luminal vs. non-Luminal), 0.658 (HER2 status), and 0.668 (TN vs. non-TN) in the independent test set. For multiclass classification, the AUC was 0.649, with superior performance in distinguishing HER2+/HR- (AUC = 0.78) and triple-negative (AUC = 0.72) subtypes. Attention heatmaps highlighted peritumoral regions as critical discriminative features.
Conclusion: The DenseNet121-CBAM model demonstrates promising capability in predicting breast cancer molecular subtypes from mammography, offering a non-invasive alternative to biopsy.
期刊介绍:
Cancer Imaging and Diagnosis is dedicated to the publication of results from clinical and research studies applied to cancer diagnosis and treatment. The section aims to publish studies from the entire field of cancer imaging: results from routine use of clinical imaging in both radiology and nuclear medicine, results from clinical trials, experimental molecular imaging in humans and small animals, research on new contrast agents in CT, MRI, ultrasound, publication of new technical applications and processing algorithms to improve the standardization of quantitative imaging and image guided interventions for the diagnosis and treatment of cancer.